Literature DB >> 23036604

Clostridium difficile-associated infection: a disease of varying severity.

Randeep S Jawa1, David W Mercer.   

Abstract

Clostridium difficile-associated infection (CDI) can have varying severity from asymptomatic carriage to fulminant colitis. Its incidence and virulence in North America are increasing. The increase in virulence is associated with emergence of the highly toxigenic North American pulsed field gel electrophoresis-1 strain. The major risk factor for CDI is exposure to antibiotics. Another major risk factor is hospitalization. The spectrum of CDI ranges from asymptomatic carriers to fulminant disease. Although asymptomatic carriers require no treatment, fulminant disease carries a substantial mortality regardless of management strategy. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036604     DOI: 10.1016/j.amjsurg.2012.05.025

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

2.  Epidemiology of Clostridium (Clostridioides) difficile Infection in Southeast Asia.

Authors:  Peng An Khun; Thomas V Riley
Journal:  Am J Trop Med Hyg       Date:  2022-08-08       Impact factor: 3.707

3.  Clostridium difficile colitis in patients undergoing lower-extremity arthroplasty: rare infection with major impact.

Authors:  Mitchell Gil Maltenfort; Mohammad R Rasouli; Todd A Morrison; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

4.  Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study.

Authors:  Young Seok Doh; You Sun Kim; Hye Jin Jung; Young Il Park; Jin Won Mo; Hyun Sung; Kyung Jin Lee; Young Ki Seo; Jeong Seop Moon; Seong Woo Hong
Journal:  Intest Res       Date:  2014-10-27

5.  A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models.

Authors:  April K Roberts; Hannah C Harris; Michael Smith; Joanna Giles; Oktawia Polak; Anthony M Buckley; Emma Clark; Duncan Ewin; Ines B Moura; William Spitall; Clifford C Shone; Mark Wilcox; Caroline Chilton; Rossen Donev
Journal:  Front Microbiol       Date:  2020-09-22       Impact factor: 5.640

6.  Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.

Authors:  Michael Maynard-Smith; Helen Ahern; Joanna McGlashan; Philip Nugent; Roger Ling; Harriet Denton; Ruth Coxon; John Landon; April Roberts; Clifford Shone
Journal:  Vaccine       Date:  2013-12-14       Impact factor: 3.641

Review 7.  Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship.

Authors:  Glorijoy Shi En Tan; Hui Lin Tay; Sock Hoon Tan; Tau Hong Lee; Tat Ming Ng; David Chien Lye
Journal:  Adv Ther       Date:  2020-08-07       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.